4D Molecular Therapeutics, Inc. (FDMT) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated May 7, 2026, announces the financial results for 4D Molecular Therapeutics, Inc. for the three months ended March 31, 2026 (First Quarter 2026). The filing serves to disclose operational highlights and expected upcoming milestones via a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are detailed in the referenced press release (Exhibit 99.1) but are not included in the cover page text of this 8-K.
Material Changes
The filing text does not provide specific data to compare current period performance against the prior comparable period. Investors must refer to the attached press release for details on material changes in financial condition or results of operations.
Guidance, Outlook, and Risks
Management commentary regarding operational highlights and expected upcoming milestones is contained within the press release referenced in Item 2.02. The filing text itself does not list specific risks, contingencies, or unusual items, nor does it provide explicit forward-looking guidance figures.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q1 2026 revenue, net loss, and cash position figures.
- Verify the details of "expected upcoming milestones" mentioned in the press release title.
- Compare Q1 2026 results against Q1 2025 data to assess year-over-year trends.
- Confirm the company's cash runway and burn rate as disclosed in the full financial statements.